JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study - Trial NCT06412848
Access comprehensive clinical trial information for NCT06412848 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Timeline & Enrollment
N/A
May 09, 2024
Jul 31, 2024
Primary Outcome
Baseline clinical and demographic characteristics,Characteristics of the first line PBCT just prior to avelumab maintenance
Summary
This study is a multicenter, non-interventional, retrospective, medical chart review of
 locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed
 avelumab as first line maintenance therapy after a platinum-based chemotherapy. This study
 aims to understand the index date (i.e., at the initiation of avelumab maintenance therapy)
 demographics and clinical characteristics of participants with locally advanced/metastatic
 Urothelial Carcinoma in Japan, and to describe their treatment patterns and outcomes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06412848
Non-Device Trial